Today: 28 January 2026
Subscribe
Browse Category

Stock Market News News 25 October 2025 - 6 November 2025

Groww IPO Day 2: Fully Subscribed (1.47x); Retail 4.65x, GMP 11–15%; Nithin Kamath Says 20% of Applications Came via Zerodha — What Top Brokerages Recommend

Groww IPO Day 2: Fully Subscribed (1.47x); Retail 4.65x, GMP 11–15%; Nithin Kamath Says 20% of Applications Came via Zerodha — What Top Brokerages Recommend

Updated: 6 Nov 2025, 4:45 pm IST What happened today (6 Nov) Subscription status: the scoreboard at a glance Snapshot reflects live tallies captured around 3:24 pm IST on Day 2. Final end‑of‑day figures can vary once the exchanges publish consolidated data. Moneycontrol A separate mid‑day cut from global wires also flagged the issue as “fully booked” by late morning…
6 November 2025
···
Nov. 6, 2025 — Lattice Semiconductor (LSCC) Matches Q3, Guides 22% Q4 Growth; Benchmark Electronics (BHE) Files 10‑Q After Mixed Quarter

Nov. 6, 2025 — Lattice Semiconductor (LSCC) Matches Q3, Guides 22% Q4 Growth; Benchmark Electronics (BHE) Files 10‑Q After Mixed Quarter

Updated Nov. 6, 2025 — Shares of Lattice Semiconductor (NASDAQ: LSCC) and Benchmark Electronics (NYSE: BHE) remain in focus today as investors digest fresh filings, analyst reactions, and guidance following this week’s earnings. Below we break down the key numbers, what changed today, and what to watch next. Key takeaways Lattice Semiconductor (LSCC): in‑line quarter, solid AI/data‑center tailwinds Lattice’s Q3…
6 November 2025
···
SNAP Stock Just Got a 48‑Hour Jolt: India Creator Boom, New Sticker Push—and a $14B TikTok Twist Investors Can’t Ignore

Snap (SNAP) earnings today — Nov. 5, 2025: Revenue up 10% to $1.51B; $400M Perplexity AI deal and $500M buyback lift sentiment

Published: November 5, 2025 At a glance (Q3 2025) What happened today Snap reported September‑quarter (Q3 2025) revenue of $1.507B, up 10% year over year, with net loss narrowing to $104M (–$0.06 per diluted share). Management also authorized a $500M repurchase program, funded from Snap’s $3.0B cash and marketable securities balance. Snap Inc. Investor Relations User engagement continued to expand:…
5 November 2025
···
Rigel Pharmaceuticals (RIGL) Stock Skyrockets on Earnings Beat – Latest Drug Updates & Analyst Outlook

Rigel Pharmaceuticals (RIGL) Stock Skyrockets on Earnings Beat – Latest Drug Updates & Analyst Outlook

Stock Price & Recent Performance 📈 Rigel’s stock has been on a tear in 2025, reflecting its improving fundamentals. As of November 5, 2025, RIGL trades around $38/share, up over 30% in a single day after its blowout Q3 earnings report Stockanalysis. The post-earnings volatility has been extreme – initially, shares fell ~7–8% in after-hours trading on Nov. 4 despite…
5 November 2025
···
Metsera (MTSR) Stock Soars 20% Amid $10B Bidding War – Pfizer vs Novo Nordisk Face Off

Metsera (MTSR) Stock Soars 20% Amid $10B Bidding War – Pfizer vs Novo Nordisk Face Off

Metsera Stock Overview and Recent Performance Metsera’s stock has been on a meteoric rise in recent weeks, capped by a 20% jump on November 4, 2025 alone Reuters Reuters. The share price is now hovering in the low $70s Reuters, a remarkable increase from just around $30–$33 in mid-September before any takeover talks emerged Prnewswire. In fact, over the past…
4 November 2025
····
Aurora Cannabis (ACB.TO) Stock Soars on CBD Buzz: In-Depth Analysis & 2025 Outlook

Aurora Cannabis (ACB.TO) Stock Soars on CBD Buzz: In-Depth Analysis & 2025 Outlook

Latest News and Catalysts (Nov 2025) Cannabis plants under cultivation. Regulatory shifts – like potential U.S. rescheduling and Germany’s cannabis reform – have sparked renewed investor interest in cannabis stocks in late 2025. In the first days of November 2025, investor attention is centered on Aurora’s upcoming earnings release (Nov 5) and broader industry news. Aurora announced it will hold…
4 November 2025
·
Kenvue (NYSE: KVUE) Stock Surges on $40B Buyout – Spin‑Off Saga, Tylenol Turmoil & Investor Outlook

Kenvue (NYSE: KVUE) Stock Surges on $40B Buyout – Spin‑Off Saga, Tylenol Turmoil & Investor Outlook

Company Overview & History Kenvue Inc. is a leading consumer health company formed from Johnson & Johnson’s storied consumer products division. The name “Kenvue” combines “ken” (knowledge) and “vue” (view), reflecting a vision of insight-driven care Wikipedia. As a spin-off, Kenvue took over J&J’s well-known retail brands, ranging from over-the-counter (OTC) medicines to skincare and baby care. Today its portfolio…
4 November 2025
····
Rani Therapeutics (RANI) Stock Surges 150% on $1B+ Chugai Collaboration – Analysts Weigh In

Rani Therapeutics (RANI) Rockets 51% on Obesity Pill Breakthrough and $1B Pharma Deal

Stock Price and Recent Performance RANI has seen explosive moves this month. As of the Oct 31 close, Rani Therapeutics stock was $2.20 (up $0.75, +51.7%) Stockanalysis. This follows a monumental rally: on Oct 17, RANI nearly tripled from ~$0.47 to an intraday high of $2.39 (+248%) ts2.tech Stockanalysis after the company announced the Chugai collaboration and financing. Even after that…
31 October 2025
···
Quantum Rocket or Bubble? RGTI’s Stunning Surge Explained—And How It Stacks Up to IonQ, D‑Wave, and QUBT

Rigetti (RGTI) Quantum Stock Skyrockets 5,000% – October 2025 News, Price & Analyst Report

Key Facts: Rigetti Computing (NASDAQ: RGTI) has been on a historic tear in 2025, rising roughly 50× from penny-stock levels to intraday highs near $56 ts2.tech. By Oct. 30, 2025 it closed around $42.52 (up 7.9% on the day) Stockanalysis. Its YTD gain (~2,800–5,000%) far eclipses peers like IonQ (+270%) or D-Wave (up thousands of %) ts2.tech. Recent catalysts include…
31 October 2025
····
Bristol Myers Squibb (NYSE:BMY) Surges on Q3 Earnings Beat and Raised Outlook – What’s Next for BMY Stock?

Bristol Myers Squibb (NYSE:BMY) Surges on Q3 Earnings Beat and Raised Outlook – What’s Next for BMY Stock?

BMY Stock Bounces After Earnings – Recent Performance Bristol Myers Squibb’s stock has been under pressure for most of 2025, but the Q3 report provided a much-needed boost. Heading into earnings, BMY shares were near 52-week lows, reflecting investor skittishness over looming patent cliffs and mixed news in prior quarters. In fact, on October 28, the stock touched a one-year…
30 October 2025
····
Skyworks Soars 18% on $22B Qorvo Merger – What’s Next for the Chipmaker?

Skyworks Soars 18% on $22B Qorvo Merger – What’s Next for the Chipmaker?

Skyworks’ stock surge on Oct. 28 was driven almost entirely by the surprise merger announcement. In pre-market trading, shares spiked ~12% Reuters, and by 9:48 a.m. ET the stock was around $89.22 (from about $75.84 Monday’s close) Investing Investing. This massive gap up reflects investor excitement: combined, Skyworks and Qorvo would control roughly $7.7 billion in annual RF-chip revenue (≈$5.1B mobile +…
28 October 2025
····
Fluence Energy Stock Skyrockets on Battery Boom – Is the FLNC Rally Here to Stay?

Fluence Energy (FLNC) Stock Skyrockets on $10B Battery Boost and AI Demand – Analysts Sound Warning

Stock Performance & Recent Volatility Fluence’s share price has been on a roller-coaster. After languishing around the mid-$5 range in early September, FLNC surged over 80% to the high teens by mid-October ts2.tech. For example, on Oct 13 the stock jumped ~21% to about $15.89, and on Oct 14 it gained another ~16% to ~$18.45 ts2.tech. In mid-October the shares…
25 October 2025
····
1 … 45 46 47 48 49

Stock Market Today

  • Brisbane Broncos (ASX:BBL) Impresses with 33% Annual EPS Growth and Insider Buying
    January 27, 2026, 7:33 PM EST. Brisbane Broncos (ASX:BBL) has demonstrated robust earnings per share (EPS) growth, increasing by 33% annually over the past three years. The company's revenue rose 14% to AU$66 million, while maintaining steady earnings before interest and tax (EBIT) margins, signaling solid operational performance. Despite a modest market capitalization of AU$161 million, insider confidence is high, highlighted by Independent Non-Executive Chairman Karl Morris purchasing AU$137,000 worth of shares at an average price of AU$0.99. These signs of financial health and committed insider buying suggest Brisbane Broncos remains a compelling pick for investors prioritizing profitable growth.
Go toTop